Mechanism:is a highly selective, short-acting glycoprotein platelet (GP) 11b/lIIa receptor inhibitor, it inhibits platelet aggregation by preventing the combination of fibrinogen and GP 11b/IIIa receptors, consequently, preventing acute myocardial ischemic events resulting from coronary thrombosis.
Uses: in combination with heparin and aspirin is indicated in the management of patients with unstable angina or non-Q-wa\@ myocardial infarction, including patients who may subsequently undergopercutaneous transluminal coronary angioplasty (PTCA), to decrease the rate of refractory ischemicconditions, new myocardial infarction and death. Dosage: rapid I.V. infusion at a rate of 0.4 Pig/kg and minute for 30 minutes, then the rate is decreased to 0.1 pg/kg and minute delivered as continuous infusion. Patients who do not show any signs of recurrent ischemic symptoms and do not undergo angiography and angioplasty should be treated for at least 48 hour.
Vial
مرة واحدة يوميا
900 EGP
Mechanism:is a highly selective, short-acting glycoprotein platelet (GP) 11b/lIIa receptor inhibitor, it inhibits platelet aggregation by preventing the combination of fibrinogen and GP 11b/IIIa receptors, consequently, preventing acute myocardial ischemic events resulting from coronary thrombosis.
Uses: in combination with heparin and aspirin is indicated in the management of patients with unstable angina or non-Q-wa\@ myocardial infarction, including patients who may subsequently undergopercutaneous transluminal coronary angioplasty (PTCA), to decrease the rate of refractory ischemicconditions, new myocardial infarction and death. Dosage: rapid I.V. infusion at a rate of 0.4 Pig/kg and minute for 30 minutes, then the rate is decreased to 0.1 pg/kg and minute delivered as continuous infusion. Patients who do not show any signs of recurrent ischemic symptoms and do not undergo angiography and angioplasty should be treated for at least 48 hour.
Note: All the provided information about this drug does not substitute for consulting a doctor.